LICENSING and IP USE
 

Our IP for HRT Pharmaceuticals and Additional Indications 
 

Liqui-Patch®  Can Deliver API's for Many Substance Groups and Indications

 

An important developmental direction that Transdermal Delivery Systems will take is “the path of increasing flexibility, controllability, directability and adjustability.

The Future of Transdermal Delivery Medicines and Use
 

Our Near Term Focus: 
Licensing Liqui-Patch® to Established HRT Pharmaceutical Companies

We are evaluating entrance to the Hormone Replacement Therapy (“HRT”) market, estimated at $20.0 B in 2017

      Estrogen / progestin market estimated at $10.0 B

      Testosterone replacement market estimated at $5.0 B
 

We plan to move hormonal therapies into our pipeline

     Female hormone replacement therapy (HRT) containing estrogens or a   
     combination of estrogens and progestins

     Male hypogonadism containing testosterone therapy
 

We are also continually reviewing additional opportunities in therapeutic areas and associated APIs

 

Contact Us for Information on Licensing Liqui-Patch® 
Technologies